Consensus-based recommendations for the management of juvenile dermatomyositis

Annals of the Rheumatic Diseases

Volumn 76, Issue 2, 2017, Pages 329-340

  Enders, Felicitas Bellutti ^a,b   Bader Meunier, Brigitte ^c   Baildam, Eileen ^d   Constantin, Tamas ^e   Dolezalova, Pavla ^f   Feldman, Brian M ^g   Lahdenne, Pekka ^h   Magnusson, Bo ⁱ   Nistala, Kiran ^j   Ozen, Seza ^k   Pilkington, Clarissa ^j   Ravelli, Angelo ^l   Russo, Ricardo ^m   Uziel, Yosef ⁿ   Van Brussel, Marco ^a   Van Der Net, Janjaap ^a   Vastert, Sebastiaan ^a   Wedderburn, Lucy R ^j   Wulffraat, Nicolaas ^a   McCann, Liza J ^d   Van Royen Kerkhof, Annet ^a   more..

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^c HÔPITAL NECKER ENFANTS MALADES   (France)

^d ALDER HEY CHILDREN'S NHS FOUNDATION TRUST   (United Kingdom)

^e Semmelweis Hospital   (Hungary)

^f CHARLES UNIVERSITY   (Czech Republic)

^g HOSPITAL FOR SICK CHILDREN   (Canada)

^h UNIVERSITY OF HELSINKI AND HELSINKI UNIVERSITY HOSPITAL   (Finland)

ⁱ KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^j UNIVERSITY COLLEGE LONDON   (United Kingdom)

^k HACETTEPE UNIVERSITY   (Turkey)

^l UNIVERSITY OF GENOA   (Italy)

^m HOSPITAL DE PEDIATRÍA PROF DR JUAN P GARRAHAN   (Argentina)

ⁿ TEL AVIV UNIVERSITY   (Israel)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ALENDRONIC ACID; AUTOANTIBODY; AZATHIOPRINE; BIOLOGICAL MARKER; CORTICOSTEROID; CREATINE KINASE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DILTIAZEM; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; INFLIXIMAB; INTERFERON; MDA5 ANTIBODY; METHOTREXATE; METHYLPREDNISOLONE; MUSCLE ENZYME; MYCOPHENOLATE MOFETIL; MYOSITIS ASSOCIATED ANTIBODY; P140 ANTIBODY; P155 ANTIBODY; PAMIDRONIC ACID; PREDNISOLONE; PREDNISONE; PROBENECID; RITUXIMAB; TACROLIMUS; UNCLASSIFIED DRUG; CYCLOSPORIN; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID; SUNSCREEN;

ARTICLE; CALCINOSIS; CLINICAL PRACTICE; CONSENSUS DEVELOPMENT; DAILY LIFE ACTIVITY; DATA BASE; DISEASE ACTIVITY; DISEASE ASSOCIATION; EUROPE; EVALUATION STUDY; EVIDENCE BASED PRACTICE; HEALTH CARE QUALITY; HEART DISEASE; HUMAN; INTERSTITIAL LUNG DISEASE; JUVENILE DERMATOMYOSITIS; MEDICAL EXPERT; MUSCULOSKELETAL DISEASE ASSESSMENT; ORGAN INJURY; PEDIATRICIAN; PHYSIOTHERAPIST; QUALITY OF LIFE; RECOMMENDED DRUG DOSE; RHEUMATOLOGIST; SKIN DISEASE ASSESSMENT; VALIDATION STUDY; DERMATOMYOSITIS; EVIDENCE BASED MEDICINE; KINESIOTHERAPY; MEDICAL SOCIETY; ORGANIZATION AND MANAGEMENT; PATIENT CARE; PRACTICE GUIDELINE;

CYCLOSPORINE; DERMATOMYOSITIS; EUROPE; EVIDENCE-BASED MEDICINE; EXERCISE THERAPY; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; METHOTREXATE; MYCOPHENOLIC ACID; PATIENT CARE TEAM; PRACTICE GUIDELINES AS TOPIC; PREDNISOLONE; RITUXIMAB; SOCIETIES, MEDICAL; SUNSCREENING AGENTS;

EID: 84981554857     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2016-209247     Document Type: Article

References (129)

1. Dougados M, Betteridge N, Burmester GR, et al. EULAR standardised operating procedures for the elaboration, evaluation, dissemination, and implementation of recommendations endorsed by the EULAR standing committees. Ann Rheum Dis 2004;63:1172-6.
2. Van der Heijde D, Aletaha D, Carmona L, et al. 2014 Update of the EULAR standardised operating procedures for EULAR-endorsed recommendations. Ann Rheum Dis 2015;74:8-13.
3. Whiting P, Rutjes AW, Dinnes J, et al. Development and validation of methods for assessing the quality of diagnostic accuracy studies. Health Technol Assess 2004;8: iii, 1-234.
4. Collaboration, T. C. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. 2013.
5. Zhang W, Doherty M, Pascual E, et al. EULAR evidence based recommendations for gout. Part I: Diagnosis. Report of a task force of the Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006;65:1301-11.
6. Zhang W, Doherty M, Bardin T, et al. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006;65:1312-24.
7. Group OCEBMLOEW. The Oxford Levels of Evidence 1. 2007. http://www.cebm.net/ocebm-levels-of-evidence/
8. Van de Ven AH, Delbecq AL. The nominal group as a research instrument for exploratory health studies. Am J Public Health 1972;62:337-42.
9. Ruperto N, Pistorio A, Oliveira S, et al. Prednisone versus prednisone plus ciclosporin versus prednisone plus methotrexate in new-onset juvenile dermatomyositis: a randomised trial. Lancet 2016;387:671-8.
10. Meyer A, Meyer N, Schaeffer M, et al. Incidence and prevalence of inflammatory myopathies: a systematic review. Rheumatology (Oxford) 2015;54:50-63.
11. Lundberg IE, Svensson J. Registries in idiopathic inflammatory myopathies. Curr Opin Rheumatol 2013;25:729-34.
12. Huber AM, Lang B, LeBlanc CM, et al. Medium-and long-term functional outcomes in a multicenter cohort of children with juvenile dermatomyositis. Arthritis Rheum 2000;43:541-9.
13. Gowdie PJ, Allen RC, Kornberg AJ, et al. Clinical features and disease course of patients with juvenile dermatomyositis. Int J Rheum Dis 2013;16:561-7.
14. Mathiesen PR, Zak M, Herlin T, et al. Clinical features and outcome in a Danish cohort of juvenile dermatomyositis patients. Clin Exp Rheumatol 2010;28:782-9.
15. Ravelli A, Trail L, Ferrari C, et al. Long-term outcome and prognostic factors of juvenile dermatomyositis: a multinational, multicenter study of 490 patients. Arthritis Care Res (Hoboken) 2010;62:63-72.
16. Stringer E, Singh-Grewal D, Feldman BM. Predicting the course of juvenile dermatomyositis: significance of early clinical and laboratory features. Arthritis Rheum 2008;58:3585-92.
17. Sanner H, Gran JT, Sjaastad I, et al. Cumulative organ damage and prognostic factors in juvenile dermatomyositis: a cross-sectional study median 16.8 years after symptom onset. Rheumatology (Oxford) 2009;48:1541-7.
18. Balin SJ, Wetter DA, Andersen LK, et al. Calcinosis cutis occurring in association with autoimmune connective tissue disease: the Mayo Clinic experience with 78 patients, 1996-2009. Arch Dermatol 2012;148:455-62.
19. Robinson AB, Reed AM. Clinical features, pathogenesis and treatment of juvenile and adult dermatomyositis. Nat Rev Rheumatol 2011;7:664-75.
20. Rider LG, Shah M, Mamyrova G, et al. The myositis autoantibody phenotypes of the juvenile idiopathic inflammatory myopathies. Medicine (Baltimore) 2013;92:223-43.
21. Robinson AB, Hoeltzel MF, Wahezi DM, et al. Clinical characteristics of children with juvenile dermatomyositis: the Childhood Arthritis and Rheumatology Research Alliance Registry. Arthritis Care Res (Hoboken) 2014;66:404-10.
22. Luca N, Feldman BM. Pediatric rheumatology: Improving the assessment of children with JIA. Nat Rev Rheumatol 2011;7:442-4.
23. Luca NJ, Feldman BM. Disease activity measures in paediatric rheumatic diseases. Int J Rheumatol 2013;2013:715352.
24. Luca NJ, Feldman BM. Health outcomes of pediatric rheumatic diseases. Best Pract Res Clin Rheumatol 2014;28:331-50.
25. Rider LG, Werth VP, Huber AM, et al. Measures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis: Physician and Patient/ Parent Global Activity, Manual Muscle Testing (MMT), Health Assessment Questionnaire (HAQ)/Childhood Health Assessment Questionnaire (C-HAQ), Childhood Myositis Assessment Scale (CMAS), Myositis Disease Activity Assessment Tool (MDAAT), Disease Activity Score (DAS), Short Form 36 (SF-36), Child Health Questionnaire (CHQ), physician global damage, Myositis Damage Index (MDI), Quantitative Muscle Testing (QMT), Myositis Functional Index-2 (FI-2), Myositis Activities Profile (MAP), Inclusion Body Myositis Functional Rating Scale (IBMFRS), Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI), Cutaneous Assessment Tool (CAT), Dermatomyositis Skin Severity Index (DSSI), Skindex, and Dermatology Life Quality Index (DLQI). Arthritis Care Res (Hoboken) 2011;63(Suppl 11):S118-57.
26. Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975;292:344-7.
27. Amato AA, Barohn R, Devisser M, et al. The International myositis classification criteria. 2005. https://www.niehs.nih.gov/research/resources/assets/docs/2005-working-committee-meeting-summary-508.pdf
28. Brown VE, Pilkington CA, Feldman BM, et al. An international consensus survey of the diagnostic criteria for juvenile dermatomyositis ( JDM). Rheumatology (Oxford) 2006;45:990-3.
29. Martin N, Krol P, Smith S, et al. A national registry for juvenile dermatomyositis and other paediatric idiopathic inflammatory myopathies: 10 years' experience; the Juvenile Dermatomyositis National (UK and Ireland) Cohort Biomarker Study and Repository for Idiopathic Inflammatory Myopathies. Rheumatology (Oxford) 2011;50:137-45.
30. Huber AM, Feldman BM, Rennebohm RM, et al. Validation and clinical significance of the Childhood Myositis Assessment Scale for assessment of muscle function in the juvenile idiopathic inflammatory myopathies. Arthritis Rheum 2004;50: 1595-603.
31. Lovell DJ, Lindsley CB, Rennebohm RM, et al. Development of validated disease activity and damage indices for the juvenile idiopathic inflammatory myopathies. II. The Childhood Myositis Assessment Scale (CMAS): a quantitative tool for the evaluation of muscle function. The Juvenile Dermatomyositis Disease Activity Collaborative Study Group. Arthritis Rheum 1999;42:2213-19.
32. Harris-Love MO, Shrader JA, Koziol D, et al. Distribution and severity of weakness among patients with polymyositis, dermatomyositis and juvenile dermatomyositis. Rheumatology (Oxford) 2009;48:134-9.
33. Jain M, Smith M, Cintas H, et al. Intra-rater and inter-rater reliability of the 10-point Manual Muscle Test (MMT) of strength in children with juvenile idiopathic inflammatory myopathies ( JIIM). Phys Occup Ther Pediatr 2006;26:5-17.
34. Lazarevic D, Pistorio A, Palmisani E, et al. The PRINTO criteria for clinically inactive disease in juvenile dermatomyositis. Ann Rheum Dis 2013;72:686-93.
35. Quiñones R, Morgan GA, Amoruso M, et al. Lack of achievement of a full score on the childhood myositis assessment scale by healthy four-year-olds and those recovering from juvenile dermatomyositis. Arthritis Care Res (Hoboken) 2013;65:1697-701.
36. Rennebohm RM, Jones K, Huber AM, et al. Normal scores for nine maneuvers of the Childhood Myositis Assessment Scale. Arthritis Rheum 2004;51:365-70.
37. Malattia C, Damasio MB, Madeo A, et al. Whole-body MRI in the assessment of disease activity in juvenile dermatomyositis. Ann Rheum Dis 2014;73: 1083-90.
38. Hernandez RJ, Sullivan DB, Chenevert TL, et al. MR imaging in children with dermatomyositis: musculoskeletal findings and correlation with clinical and laboratory findings. AJR Am J Roentgenol 1993;161:359-66.
39. Davis WR, Halls JE, Offiah AC, et al. Assessment of active inflammation in juvenile dermatomyositis: a novel magnetic resonance imaging-based scoring system. Rheumatology (Oxford) 2011;50:2237-44.
40. McCann LJ, Juggins AD, Maillard SM, et al. The Juvenile Dermatomyositis National Registry and Repository (UK and Ireland)-clinical characteristics of children recruited within the first 5 yr. Rheumatology (Oxford) 2006;45:1255-60.
41. Ghosh PS, Sorenson EJ. Diagnostic yield of electromyography in children with myopathic disorders. Pediatr Neurol 2014;51:215-19.
42. Wedderburn LR, Varsani H, Li CK, et al. International consensus on a proposed score system for muscle biopsy evaluation in patients with juvenile dermatomyositis: a tool for potential use in clinical trials. Arthritis Rheum 2007;57:1192-201.
43. Cappelletti C, Baggi F, Zolezzi F, et al. Type I interferon and Toll-like receptor expression characterizes inflammatory myopathies. Neurology 2011;76:2079-88.
44. Sallum AM, Kiss MH, Silva CA, et al. MHC class I and II expression in juvenile dermatomyositis skeletal muscle. Clin Exp Rheumatol 2009;27:519-26.
45. Shinjo SK, Sallum AM, Silva CA, et al. Skeletal muscle major histocompatibility complex class I and II expression differences in adult and juvenile dermatomyositis. Clinics (Sao Paulo) 2012;67:885-90.
46. Goncalves FG, Chimelli L, Sallum AM, et al. Immunohistological analysis of CD59 and membrane attack complex of complement in muscle in juvenile dermatomyositis. J Rheumatol 2002;29:1301-7.
47. Li CK, Varsani H, Holton JL, et al. MHC Class I overexpression on muscles in early juvenile dermatomyositis. J Rheumatol 2004;31:605-9.
48. Sallum AM, Kiss MH, Silva CA, et al. Difference in adhesion molecule expression (ICAM-1 and VCAM-1) in juvenile and adult dermatomyositis, polymyositis and inclusion body myositis. Autoimmun Rev 2006;5:93-100.
49. Newman ED, Garbes AD. Needle muscle biopsy. J Clin Rheumatol 1997;3:69-74.
50. Bhansing KJ, Hoppenreijs EP, Janssen AJ, et al. Quantitative muscle ultrasound: a potential tool for assessment of disease activity in juvenile ermatomyositis. Scand J Rheumatol 2014;43:339-41.
51. Habers GE, Van Brussel M, Bhansing KJ, et al. Quantitative muscle ultrasonography in the follow-up of juvenile dermatomyositis. Muscle Nerve 2015;52:540-6.
52. McCann LJ, Garay SM, Ryan MM, et al. Oropharyngeal dysphagia in juvenile dermatomyositis ( JDM): an evaluation of videofluoroscopy swallow study (VFSS) changes in relation to clinical symptoms and objective muscle scores. Rheumatology (Oxford) 2007;46:1363-6.
53. Dolezalova P, Young SP, Bacon PA, et al. Nailfold capillary microscopy in healthy children and in childhood rheumatic diseases: a prospective single blind observational study. Ann Rheum Dis 2003;62:444-9.
54. Ingegnoli F, Zeni S, Gerloni V, et al. Capillaroscopic observations in childhood rheumatic diseases and healthy controls. Clin Exp Rheumatol 2005;23:905-11.
55. Nascif AK, Terreri MT, Len CA, et al. Inflammatory myopathies in childhood: correlation between nailfold capillaroscopy findings and clinical and laboratory data. J Pediatr (Rio J) 2006;82:40-5.
56. Piotto DG, Len CA, Hilario MO, et al. Nailfold capillaroscopy in children and adolescents with rheumatic diseases. Rev Bras Reumatol 2012;52:722-32.
57. Scheja A, Elborgh R, Wildt M. Decreased capillary density in juvenile dermatomyositis and in mixed connective tissue disease. J Rheumatol 1999;26:1377-81.
58. Schmeling H, Stephens S, Goia C, et al. Nailfold capillary density is importantly associated over time with muscle and skin disease activity in juvenile dermatomyositis. Rheumatology (Oxford) 2011;50:885-93.
59. Huber AM, Dugan EM, Lachenbruch PA, et al. The Cutaneous Assessment Tool: development and reliability in juvenile idiopathic inflammatory myopathy. Rheumatology (Oxford) 2007;46:1606-11.
60. Huber AM, Lachenbruch PA, Dugan EM, et al. Alternative scoring of the Cutaneous Assessment Tool in juvenile dermatomyositis: results using abbreviated formats. Arthritis Rheum 2008;59:352-6.
61. Huber AM, Dugan EM, Lachenbruch PA, et al. Preliminary validation and clinical meaning of the Cutaneous Assessment Tool in juvenile dermatomyositis. Arthritis Rheum 2008;59:214-21.
62. Mathiesen PR, Buchvald F, Nielsen KG, et al. Pulmonary function and autoantibodies in a long-term follow-up of juvenile dermatomyositis patients. Rheumatology (Oxford) 2014;53:644-9.
63. Pouessel G, Deschildre A, Le Bourgeois M, et al. The lung is involved in juvenile dermatomyositis. Pediatr Pulmonol 2013;48:1016-25.
64. Prestridge A, Morgan G, Ferguson L, et al. Pulmonary function tests in idiopathic inflammatory myopathy: association with clinical parameters in children. Arthritis Care Res (Hoboken) 2013;65:1424-31.
65. Schwartz T, Sanner H, Gjesdal O, et al. In juvenile dermatomyositis, cardiac systolic dysfunction is present after long-term follow-up and is predicted by sustained early skin activity. Ann Rheum Dis 2014;73:1805-10.
66. Karaca NE, Aksu G, Yeniay BS, et al. Juvenile dermatomyositis with a rare and remarkable complication: sinus bradycardia. Rheumatol Int 2006;27:179-82.
67. Pereira RM, Lerner S, Maeda WT, et al. Pericardial tamponade in juvenile dermatomyositis. Clin Cardiol 1992;15:301-3.
68. Schwartz T, Sanner H, Husebye T, et al. Cardiac dysfunction in juvenile dermatomyositis: a case-control study. Ann Rheum Dis 2011;70:766-71.
69. Shahi V, Wetter DA, Howe BM, et al. Plain radiography is effective for the detection of calcinosis cutis occurring in association with autoimmune connective tissue disease. Br J Dermatol 2014;170:1073-9.
70. Guzman J, Petty RE, Malleson PN. Monitoring disease activity in juvenile dermatomyositis: the role of von Willebrand factor and muscle enzymes. J Rheumatol 1994;21:739-43.
71. Ramanan AV, Campbell-Webster N, Ota S, et al. The effectiveness of treating juvenile dermatomyositis with methotrexate and aggressively tapered corticosteroids. Arthritis Rheum 2005;52:3570-8.
72. Rider LG. Assessment of disease activity and its sequelae in children and adults with myositis. Curr Opin Rheumatol 1996;8:495-506.
73. Ruperto N, Ravelli A, Pistorio A, et al. The provisional Paediatric Rheumatology International Trials Organisation/American College of Rheumatology/European League Against Rheumatism Disease activity core set for the evaluation of response to therapy in juvenile dermatomyositis: a prospective validation study. Arthritis Rheum 2008;59:4-13.
74. Ruperto N, Pistorio A, Ravelli A, et al. The Paediatric Rheumatology International Trials Organisation provisional criteria for the evaluation of response to therapy in juvenile dermatomyositis. Arthritis Care Res (Hoboken) 2010;62:1533-41.
75. Bloom BJ, Tucker LB, Miller LC, et al. von Willebrand factor in juvenile dermatomyositis. J Rheumatol 1995;22:320-5.
76. Bilgic H, Ytterberg SR, Amin S, et al. Interleukin-6 and type I interferon-regulated genes and chemokines mark disease activity in dermatomyositis. Arthritis Rheum 2009;60:3436-46.
77. Reed AM, Peterson E, Bilgic H, et al. Changes in novel biomarkers of disease activity in juvenile and adult dermatomyositis are sensitive biomarkers of disease course. Arthritis Rheum 2012;64:4078-86.
78. Bellutti Enders F, van Wijk F, Scholman R, et al. Correlation of CXCL10, tumor necrosis factor receptor type II, and galectin 9 with disease activity in juvenile dermatomyositis. Arthritis Rheumatol 2014;66:2281-9.
79. Rider LG, Schiffenbauer AS, Zito M, et al. Neopterin and quinolinic acid are surrogate measures of disease activity in the juvenile idiopathic inflammatory myopathies. Clin Chem 2002;48:1681-8.
80. Pachman LM, Friedman JM, Maryjowski-Sweeney ML, et al. Immunogenetic studies of juvenile dermatomyositis. III. Study of antibody to organ-specific and nuclear antigens. Arthritis Rheum 1985;28:151-7.
81. Gunawardena H. The clinical features of myositis-associated autoantibodies: a review. Clin Rev Allergy Immunol. doi:10.1007/s12016-015-8513-8
82. Tansley SL, McHugh NJ. Myositis specific and associated autoantibodies in the diagnosis and management of juvenile and adult idiopathic inflammatory myopathies. Curr Rheumatol Rep 2014;16:464.
83. Ishikawa A, Muro Y, Sugiura K, et al. Development of an ELISA for detection of autoantibodies to nuclear matrix protein 2. Rheumatology (Oxford) 2012;51:1181-7.
84. Tansley SL, Betteridge ZE, Shaddick G, et al. Calcinosis in juvenile dermatomyositis is influenced by both anti-NXP2 autoantibody status and age at disease onset. Rheumatology (Oxford) 2014;53:2204-8.
85. Bodoki L, Nagy-Vincze M, Griger Z, et al. Four dermatomyositis-specific autoantibodies-anti-TIF1γ, anti-NXP2, anti-SAE and anti-MDA5-in adult and juvenile patients with idiopathic inflammatory myopathies in a Hungarian cohort. Autoimmun Rev 2014;13:1211-19.
86. Espada G, Maldonado Cocco JA, Fertig N, et al. Clinical and serologic characterization of an Argentine pediatric myositis cohort: identification of a novel autoantibody (anti-MJ) to a 142-kDa protein. J Rheumatol. 2009;36:2547-51.
87. Gunawardena H, Wedderburn LR, North J, et al. Clinical associations of autoantibodies to a p155/140 kDa doublet protein in juvenile dermatomyositis. Rheumatology (Oxford) 2008;47:324-8.
88. Gunawardena H, Wedderburn LR, Chinoy H, et al. Autoantibodies to a 140-kd protein in juvenile dermatomyositis are associated with calcinosis. Arthritis Rheum 2009;60:1807-14.
89. Kobayashi I, Okura Y, Yamada M, et al. Anti-melanoma differentiationassociated gene 5 antibody is a diagnostic and predictive marker for interstitial lung diseases associated with juvenile dermatomyositis. J Pediatr 2011;158:675-7.
90. Tansley SL, Betteridge ZE, Gunawardena H, et al. Anti-MDA5 autoantibodies in juvenile dermatomyositis identify a distinct clinical phenotype: a prospective cohort study. Arthritis Res Ther 2014;16:R138.
91. Fisler RE, Liang MG, Fuhlbrigge RC, et al. Aggressive management of juvenile dermatomyositis results in improved outcome and decreased incidence of calcinosis. J Am Acad Dermatol 2002;47:505-11.
92. Al-Mayouf S, Al-Mazyed A, Bahabri S. Efficacy of early treatment of severe juvenile dermatomyositis with intravenous methylprednisolone and methotrexate. Clin Rheumatol 2000;19:138-41.
93. Miller LC, Sisson BA, Tucker LB, et al. Methotrexate treatment of recalcitrant childhood dermatomyositis. Arthritis Rheum 1992;35:1143-9.
94. Fischer TJ, Rachelefsky GS, Klein RB, et al. Childhood dermatomyositis and polymyositis. Treatment with methotrexate and prednisone. Am J Dis Child 1979;133:386-9.
95. Hasija R, Pistorio A, Ravelli A, et al. Therapeutic approaches in the treatment of juvenile dermatomyositis in patients with recent-onset disease and in those experiencing disease flare: an international multicenter PRINTO study. Arthritis Rheum 2011;63:3142-52.
96. Oddis CV, Reed AM, Aggarwal R, et al. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum 2013;65: 314-24.
97. Huber AM, Giannini EH, Bowyer SL, et al. Protocols for the initial treatment of moderately severe juvenile dermatomyositis: results of a Children's Arthritis and Rheumatology Research Alliance Consensus Conference. Arthritis Care Res (Hoboken) 2010;62:219-25.
98. Aggarwal R, Bandos A, Reed AM, et al. Predictors of clinical improvement in rituximab-treated refractory adult and juvenile dermatomyositis and adult polymyositis. Arthritis Rheumatol 2014;66:740-9.
99. Al-Mayouf SM, Laxer RM, Schneider R, et al. Intravenous immunoglobulin therapy for juvenile dermatomyositis: efficacy and safety. J Rheumatol 2000;27:2498-503.
100. Lam CG, Manlhiot C, Pullenayegum EM, et al. Efficacy of intravenous Ig therapy in juvenile dermatomyositis. Ann Rheum Dis 2011;70:2089-94.
101. Yang M-C, Lee J-H, Yang Y-H, et al. Improvement of juvenile dermatomyositis with calcinosis universalis after treatment with intravenous immunoglobulin. Int J Rheum Dis 2008;11:77-80.
102. Riley P, Maillard SM, Wedderburn LR, et al. Intravenous cyclophosphamide pulse therapy in juvenile dermatomyositis. A review of efficacy and safety. Rheumatology (Oxford) 2004;43:491-6.
103. Heckmatt J, Hasson N, Saunders C, et al. Cyclosporin in juvenile dermatomyositis. Lancet 1989;1:1063-6.
104. Jacobs JC. Methotrexate and azathioprine treatment of childhood dermatomyositis. Pediatrics 1977;59:212-8.
105. Miller LC, Michael AF, Kim Y. Childhood dermatomyositis. Clinical course and long-term follow-up. Clin Pediatr (Phila) 1987;26:561-6.
106. Ng YT, Ouvrier RA, Wu T. Drug therapy in juvenile dermatomyositis: follow-up study. J Child Neurol 1998;13:109-12.
107. Rouster-Stevens KA, Morgan GA, Wang D, et al. Mycophenolate mofetil: a possible therapeutic agent for children with juvenile dermatomyositis. Arthritis Care Res (Hoboken) 2010;62:1446-51.
108. Olson NY, Lindsley CB. Adjunctive use of hydroxychloroquine in childhood dermatomyositis. J Rheumatol 1989;16:1545-7.
109. Hassan J, van der Net JJ, van Royen-Kerkhof A. Treatment of refractory juvenile dermatomyositis with tacrolimus. Clin Rheumatol 2008;27:1469-71.
110. Bader-Meunier B, Decaluwe H, Barnerias C, et al. Safety and efficacy of rituximab in severe juvenile dermatomyositis: results from 9 patients from the French Autoimmunity and Rituximab registry. J Rheumatol 2011;38: 1436-40.
111. Riley P, McCann LJ, Maillard SM, et al. Effectiveness of infliximab in the treatment of refractory juvenile dermatomyositis with calcinosis. Rheumatology (Oxford) 2008;47:877-80.
112. Holzer U, van Royen-Kerkhof A, van der Torre P, et al. Successful autologous stem cell transplantation in two patients with juvenile dermatomyositis. Scand J Rheumatol 2010;39:88-92.
113. Ambler GR, Chaitow J, Rogers M, et al. Rapid improvement of calcinosis in juvenile dermatomyositis with alendronate therapy. J Rheumatol 2005;32: 1837-9.
114. Arabshahi B, Silverman RA, Jones OY, et al. Abatacept and sodium thiosulfate for treatment of recalcitrant juvenile dermatomyositis complicated by ulceration and calcinosis. J Pediatr 2012;160:520-2.
115. Bertorini TE, Sebes JI, Palmieri GM, et al. Diltiazem in the treatment of calcinosis in juvenile dermatomyositis. J Clin Neuromuscul Dis 2001;2:191-3.
116. Harel L, Harel G, Korenreich L, et al. Treatment of calcinosis in juvenile dermatomyositis with probenecid: the role of phosphorus metabolism in the development of calcifications. J Rheumatol 2001;28:1129-32.
117. Ichiki Y, Akiyama T, Shimozawa N, et al. An extremely severe case of cutaneous calcinosis with juvenile dermatomyositis, and successful treatment with diltiazem. Br J Dermatol 2001;144:894-7.
118. Jazayeri SB, Mehdizadeh M, Shahlaee A. Sketched x-rays: Calcinosis universalis. Eur J Pediatr 2012;171:1577-8.
119. Jiang X, Yi Q, Liu D, et al. A case of juvenile dermatomyositis with severe calcinosis and successful treatment with prednisone and diltiazem. Int J Dermatol 2011;50:74-7.
120. Kaliyadan F, Venkitakrishnan S. Late onset calcification following juvenile dermatomyositis: response with weekly alendronate. Indian J Dermatol 2011;56:357-9.
121. Marco Puche A, Calvo Penades I, Lopez Montesinos B. Effectiveness of the treatment with intravenous pamidronate in calcinosis in juvenile dermatomyositis. Clin Exp Rheumatol 2010;28:135-40.
122. Nakamura H, Kawakami A, Ida H, et al. Efficacy of probenecid for a patient with juvenile dermatomyositis complicated with calcinosis. J Rheumatol 2006;33:1691-3.
123. Slimani S, Abdessemed A, Haddouche A, et al. Complete resolution of universal calcinosis in a patient with juvenile dermatomyositis using pamidronate. Joint Bone Spine 2010;77:70-2.
124. Touimy M, Janani S, Rachidi W, et al. Calcinosis universalis complicating juvenile dermatomyositis: improvement after intravenous immunoglobulin therapy. Joint Bone Spine 2013;80:108-9.
125. Rider LG, Giannini EH, Brunner HI, et al. International consensus on preliminary definitions of improvement in adult and juvenile myositis. Arthritis Rheum 2004;50:2281-90.
126. Huber AM, Robinson AB, Reed AM, et al. Consensus treatments for moderate juvenile dermatomyositis: beyond the first two months. Results of the second Childhood Arthritis and Rheumatology Research Alliance consensus conference. Arthritis Care Res (Hoboken) 2012;64:546-53.
127. Sanner H, Sjaastad I, Flatø B. Disease activity and prognostic factors in juvenile dermatomyositis: a long-term follow-up study applying the Paediatric Rheumatology International Trials Organization criteria for inactive disease and the myositis disease activity assessment tool. Rheumatology (Oxford) 2014;53:1578-85.
128. Almeida B, Campanilho-Marques R, Arnold K, et al. Analysis of published criteria for clinically inactive disease in a large juvenile dermatomyositis cohort shows that skin disease is underestimated. Arthritis Rheumatol 2015;67:2495-502.
129. Wulffraat NM, Vastert B, SHARE C. Time to share. Pediatr Rheumatol Online J 2013;11:5.